Modern Lymphoma Treatment: Personalized, Targeted Breakthroughs
Received Date: May 02, 2025 / Accepted Date: May 30, 2025 / Published Date: May 30, 2025
Abstract
Recent advancements across various lymphoma subtypes have transformed diagnosis and treatment paradigms. Targeted ther apies, including BTK, PI3K, BCL-2 inhibitors, and novel immunotherapies like CAR T-cells and checkpoint inhibitors, are now central to managing B-cell non-Hodgkin, Hodgkin, mantle cell, DLBCL, and follicular lymphomas. Progress in molecular and ge netic profiling enables more precise diagnoses and personalized medicine. Risk-adapted strategies and agents like histone deacetylase inhibitors are improving outcomes for pediatric Hodgkin and challenging T-cell lymphomas. These innovations collectively aim to enhance efficacy, reduce toxicity, and offer superior, individualized patient care.
Citation: Kov脙隆cs A (2025) Modern Lymphoma Treatment: Personalized, Targeted Breakthroughs. jcd 09: 302
Copyright: 漏 2025 Anna Kov谩cs This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use,distribution and reproduction in any medium, provided the original author and source are credited.
Select your language of interest to view the total content in your interested language
Share This Article
Recommended Journals
Open Access Journals
Article Usage
- Total views: 375
- [From(publication date): 0-0 - Apr 07, 2026]
- Breakdown by view type
- HTML page views: 310
- PDF downloads: 65
